Markets:

Overview

News

Currencies

International

Treasuries

Vivani Medical, Inc. - Common Stock (NQ:VANI)

1.410 +0.010 (+0.71%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vivani Medical, Inc. - Common Stock

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 17, 2025

Via Benzinga

Which stocks are experiencing notable movement on Wednesday? ↗

September 17, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Discover the top movers in Wednesday's pre-market session. ↗

September 17, 2025

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 17, 2025

Via Benzinga

EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data ↗

August 05, 2025

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 13, 2025

Via Benzinga

EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs ↗

April 15, 2025

Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions.

Via Benzinga

Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars ↗

March 26, 2025

The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that...

Via Stocktwits

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing ↗

March 26, 2025

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Via Benzinga

Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

March 24, 2025

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

March 13, 2025

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗

March 13, 2025

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

Via Benzinga

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

March 12, 2025

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value ↗

March 12, 2025

Vivani Medical plans to spin off Cortigent into a separate public company, aiming to expand neurostimulation technology while focusing on its drug implants.

Via Benzinga

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

December 19, 2024

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia ↗

December 19, 2024

Vivani Medical launches first-in-human trial of its exenatide implant in Australia, aiming to support chronic weight management with innovative GLP-1 technology.

Via Benzinga

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

December 04, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results

November 13, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024

October 22, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

September 26, 2024

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia ↗

September 26, 2024

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial will assess safety, tolerability, and weight loss outcomes, with data expected...

Via Benzinga

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

September 23, 2024

From Vivani Medical, Inc.

Via Business Wire

Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant

September 04, 2024

From Vivani Medical, Inc.

Via Business Wire

EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity ↗

September 04, 2024

Vivani Medical reports promising preclinical liver fat reduction results with its exenatide implant for obesity, showing potential as a differentiated treatment option. The LIBERATE-1 clinical trial is...

Via Benzinga

Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

August 28, 2024

From Vivani Medical, Inc.

Via Business Wire

VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024 ↗

August 13, 2024

VANI stock results show that Vivani Medical beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results

August 13, 2024

From Vivani Medical, Inc.

Via Business Wire

Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying ↗

August 05, 2024

Via Benzinga

Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying ↗

August 02, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.